Drugs in R & D

, Volume 2, Issue 6, pp 431–435 | Cite as

Suramin Sodium

CI 1003, Metaret®, Suramin, Suramin Hexasodium
Section 2: Men’s Health Adis R&D Profile


Prostate Cancer Adis International Limited Suramin Flutamide Intermittent Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Falcone A, Antonuzzo A, Danesi R, et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 1999 Aug 1; 86: 470–6PubMedCrossRefGoogle Scholar
  2. 2.
    Kobayashi K, Vokes EE, Vogelzang NJ, et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995 Sep; 13: 2196–207PubMedGoogle Scholar
  3. 3.
    Arit W, Reincke M, Siekmann L, et al. Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clin Endocrinol 1994 Sep; 41: 299–307CrossRefGoogle Scholar
  4. 4.
    Bowden CJ, Figg WD, Dawson NA, et al. Aphase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol 1996 Nov–Dec; 39: 1–8PubMedCrossRefGoogle Scholar
  5. 5.
    Bitton RJ, Figg WD, Venzon DJ, et al. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 1995 Sep; 13: 2223–9PubMedGoogle Scholar
  6. 6.
    Mirza MR, Jakobsen E, Pfeiffer P, et al. Suramin in non-small cell lung cancer and advanced breast cancer: two parallel phase II studies. Acta Oncologica 1997; 36 No. 2: 171–4PubMedCrossRefGoogle Scholar
  7. 7.
    Woll PJ, Ranson M, Margison J, et al. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. Ann Oncol 1994 Sep; 5: 597–600PubMedGoogle Scholar
  8. 8.
    Cole DJ, Ettinghausen SE, Pass HI, et al. Postoperative complications in patients receiving suramin therapy. Surgery 1994 Jul; 116: 90–5PubMedGoogle Scholar
  9. 9.
    Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995 Sep; 13: 2174–86PubMedGoogle Scholar
  10. 10.
    Dawson NA, Figg WD, Cooper MR, et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997 Apr; 15: 1470–7PubMedGoogle Scholar
  11. 11.
    Piscitelli SC, Forrest A, Lush RM, et al. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics. Pharmacotherapy 1997 May–Jun; 17: 431–7PubMedGoogle Scholar
  12. 12.
    Kloen P, Jennings CL, Gebhardt MC, et al. Suramin inhibits growth and transforming growth factor-beta-1 (TGF-beta-1) binding in osteosarcoma cell lines. Eur J Cancer 1994; 30 (5 Pt A): 678–82CrossRefGoogle Scholar
  13. 13.
    Lindman H, Taube A, Bergh JCS. Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein. Anticancer Res 1994 Mar–Apr; 14 (2A): 363–6PubMedGoogle Scholar
  14. 14.
    Lopez Lopez R, van Rijswijk REN, Wagstaff J, et al. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. Eur J Cancer 1994; 30 (10 Pt A): 1545–9CrossRefGoogle Scholar
  15. 15.
    Kikuchi Y, Hirata J, Hisano A, et al. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). Gynecol Oncol 1995 Jul; 58: 11–5PubMedCrossRefGoogle Scholar
  16. 16.
    Small EJ, Marshall ME, Reyno L, et al. Superiority of suramin plus hydrocortisone over placebo plus hydrocortisone: results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–18; Los Angeles, 17: 308Google Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations